ArticleBiotechnology reports (Amsterdam, Netherlands)2022
Perspectives on nano-nutraceuticals to manage pre and post COVID-19 infections.
Article in Biotechnology reports (Amsterdam, Netherlands), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 33 citations in OpenAlex.
- Metal oxide nanoparticles as promising agents for triggering defense mechanisms in plants against bacterial diseases.Discover nano · 2025Review
- Overcoming the Low-Stability Bottleneck in the Clinical Translation of Liposomal Pressurized Metered-Dose Inhalers: A Shell Stabilization Strategy Inspired by Biomineralization.International journal of molecular sciences · 2024Review
- Urolithin A in Health and Diseases: Prospects for Parkinson's Disease Management.Antioxidants (Basel, Switzerland) · 2023Review
- Recent trends in carbon nanotube (CNT)-based biosensors for the fast and sensitive detection of human viruses: a critical review.Nanoscale advances · 2023Review
- Potential of Nano-Antioxidants and Nanomedicine for Recovery from Neurological Disorders Linked to Long COVID Syndrome.Antioxidants (Basel, Switzerland) · 2023Review
- Aspects of Nanotechnology for COVID-19 Vaccine Development and Its Delivery Applications.Pharmaceutics · 2023Review
- Curcumin Transferosome-Loaded Thermosensitive Intranasal in situ Gel as Prospective Antiviral Therapy for SARS-Cov-2.International journal of nanomedicine · 2023Article
- Omicron variant: Current insights and future directions.Microbiological research · 2022Review
- Ginkgo biloba in the management of the COVID-19 severity.Archiv der Pharmazie · 2022Review
- Are Nutraceuticals Effective in COVID-19 and Post-COVID Prevention and Treatment?Foods (Basel, Switzerland) · 2022Review
- Editorial: Biological and biotechnological applications of natural bioactives.Biotechnology reports (Amsterdam, Netherlands) · 2022Article
- OMICRON: Virology, immunopathogenesis, and laboratory diagnosis.The journal of gene medicine · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimized therapeutic bio-compounds supported by bio-acceptable nanosystems (i.e., precise nanomedicine) have ability to promote health via maintaining body structure, organ function, and controlling chronic and acute effects. Therefore, nano-nutraceuticals (designed to neutralize virus, inhibit virus bindings with receptors, and support immunity) utilization can manage COVID-19 pre/post-infection effects. To explore these approaches well, our mini-review explores optimized bio-active compounds, their ability to influence SARS-CoV-2 infection, improvement in performance supported by precise nanomedicine approach, and challenges along with prospects. Such optimized pharmacologically relevant therapeutic cargo not only affect SARS-CoV-2 but will support other organs which show functional alternation due to SARS-CoV-2 for example, neurological functions. Hence, coupling the nutraceuticals with the nano-pharmacology perspective of higher efficacy via targeted delivery action can pave a novel way for health experts to plan future research needed to manage post COVID-19 infection effect where a longer efficacy with no side-effects is a key requirement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.